Protagonist Q3 net loss narrows to $33.2 million; cash totals $583.3 million
Protagonist Therapeutics reported third quarter 2024 results, with license and collaboration revenue of $4.7 million, compared with none in the prior-year quarter. The net loss narrowed to $33.2 million, or $0.54 per share, from $34.1 million, or $0.58 per share, a year earlier, and the company said its cash runway extends through the end of 2027.
Key points
- Q3 2024 license and collaboration revenue was $4.7 million, versus $0 in Q3 2023.
- Q3 2024 net loss was $33.2 million ($0.54 per share), versus $34.1 million ($0.58 per share) in Q3 2023.
- Nine-month 2024 net income was $143.5 million ($2.22 per diluted share), driven by a $255.0 million Takeda upfront payment recognized in Q1 2024.
- Cash, cash equivalents and marketable securities were $583.3 million at September 30, 2024, which the company says provides runway through end of 2027.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 07, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.